Skip NavigationSkip to Content
Return Return to Search Results

A dose sparing effect by plasmid encoded IL-12 adjuvant on a SlVgag-plasmid DNA vaccine in rhesus macaques

  1. Author:
    Schadeck, E. B.
    Sidhu, M.
    Egan, M. A.
    Chong, S. Y.
    Piacente, P.
    Masood, A.
    Garcia-H, D.
    Cappello, S.
    Roopch, V.
    Megati, S.
    Quiroz, J.
    Boyer, J. D.
    Felber, B. K.
    Pavlakis, G. N.
    Weiner, D. B.
    Eldridge, J. H.
    Israel, Z. R.

  2. Author Address

    Wyeth Vaccines Res, Pearl River, NY 10965 USA. Wyeth Res, Pearl River, NY 10965 USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. NCI, Basic Res Lab, Human Retrovirus Sect, Frederick, MD 21702 USA.;Israel, ZR, Wyeth Vaccines Res, 401 N,Middletown Rd,Bldg 180-258-12, Pearl River, NY 10965 USA.;israelz@wyeth.com
    1. Year: 2006
    2. Date: May
  2. Journal: Vaccine
    1. 24
    2. 21
    3. Pages: 4677-4687
  4. Type of Article: Article
  5. ISSN: 0264-410X
  1. Abstract:

    An experimental pDNA vaccine adjuvant expressing IL-12 was evaluated for its ability to augment the humoral and cellular immune responses elicited by a SIVmac239 gag p39 expressing pDNA vaccine. To determine the effect of vaccine dose on the immune response, rhesus macaques were immunized with 1.5 mg or 5.0 mg of SIVmac239 gag pDNA, with or without co-immunization of IL-12 pDNA at 1.5 mg and 5.0 mg, respectively. Serum antibody responses to simian immunodeficiency virus (SIV) gag were increased 10-fold (p = 0.044, 0.002) in macaques receiving IL-12 pDNA. Cellular immune responses, monitored by SIV gag-specific IFN-gamma ELISpot assay, were also significantly higher (p = 0.007 0.019) when the pDNA vaccine was co-immunized with IL-12 pDNA at high and low doses. There was no statistical difference between the immune responses elicited by the high and low dose of IL-12 pDNA (p=0.221, 0.917), a finding which could allow a dose reduction of vaccine without the concomitant loss of imunogenicity. Furthermore, analysis of the breadth of the T-cell response during the vaccination schedule, using overlapping peptides to SIV gag, demonstrated a significant correlation (p = 0.0002) between the magnitude and breadth of the immune responses in the vaccines. These results have important implications for the continuing development of an effective, safe low dose pDNA vaccine adjuvant suitable for human use. (c) 2005 Elsevier Ltd. All rights reserved.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.vaccine.2005.10.035
  3. View record in Web of Science®
  4. WOS: 000238518400041

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel